Pharmaids Pharmaceuticals Faces Mixed Financial Signals Amid Growth and Challenges
Pharmaids Pharmaceuticals has recently adjusted its evaluation, reflecting a mix of growth and challenges in its financial metrics. While net sales showed significant growth, the company reported a loss in profit after tax. Operational efficiency indicators present a complex financial landscape, with mixed signals from technical metrics.
Pharmaids Pharmaceuticals has recently undergone an evaluation adjustment, reflecting changes in its financial and technical metrics. The company, operating within the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ending March 2025. Notably, net sales for the latest six months reached Rs 9.48 crore, showcasing a growth rate of 62.61%. However, the company has also faced challenges, with a reported profit after tax (PAT) of Rs -4.00 crore, indicating a decline of 31.3% compared to the previous four-quarter average.In terms of operational efficiency, the debtors turnover ratio stands at a robust 14.63 times, yet the debt-equity ratio has reached a high of 0.62 times, raising concerns about the company's leverage. Additionally, the interest expense has peaked at Rs 1.01 crore, further complicating its financial landscape.
On the technical side, the stock's trend has shifted to a sideways movement, suggesting a lack of clear price momentum. The technical indicators, including MACD and RSI, reflect mixed signals, with some metrics indicating bearish tendencies.
Overall, the evaluation adjustment for Pharmaids Pharmaceuticals highlights a complex interplay of growth and challenges within its financial framework.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
